Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmoglein 1 and 3 antibody levels after rituximab in pemphigus
IRCT20220117053747N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in pemphigus, sponsored by Tabriz University of Medical Sciences. Primary endpoints: Desmoglein 1 antibody level and Desmoglein 3 antibody level. Started Mar 2022; status: completed.
02
Drugs
rituximab
03
Conditions
pemphigus
Beyond the preview
Go deeper on IRCT20220117053747N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220117053747N1.